This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics Europe
6 - 8 June, 2023
Postillon Hotel AmsterdamDigital Experience: All Sessions Live-streamed 6-8 June, 2023

Sara Majocchi
Discovery Program Leader at Light Chain Bioscience


Sara Majocchi is a Discovery Program Leader at Light Chain Bioscience (a brand of Novimmune SA), based in Geneva, Switzerland. She obtained her master’s degree in biotechnology from the École Supérieure de Biotechnologie de Strasbourg, Louis Pasteur University, France and her PhD in Life Science from the University of Lausanne, Switzerland. After graduation, Sara joined the Research Department of Light Chain Bioscience where her focus was on developing mouse models to support the preclinical development of the first bispecific therapeutic programs targeting CD47. Since 2018, she has been leading the discovery of therapeutic bispecific antibodies, from early discovery to clinical lead candidate selection.

Agenda Sessions

  • Conditional Costimulation of T cells with CD28 Bispecific Antibodies